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 ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Do BRAF 
inhibitors improve survival in patients with BRAF V600E mutant melanoma?” 
 
STUDY DESIGN: Review of primary literature sources that examined survival rates in BRAF V600E 
mutant melanoma patients receiving treatment with a BRAF inhibitor.     
 
DATA SOURCES: Two randomized controlled trials and one cohort study evaluating the use of BRAF 
inhibitors in patients with BRAF V600E mutant melanoma were found using OVID, Medline, and 
PubMed. 
 
OUTCOMES MEASURED: Overall survival and progression free survival were the outcomes 
measured to determine survival rates in patients with BRAF V600E mutant melanoma.     
 
RESULTS: Chapman et al demonstrates an overall survival rate of 84% for Vemurafenib (95% CI, 78-
89) compared to 64% for Dacarbazine (95% CI, 56-73).  Progression free survival was 5.3 months for 
Vemurafenib compared to 1.6 months for Dacarbazine.    
 
Sosman et al, a cohort study, demonstrates an overall survival rate of 58% (95% CI, 49-67) after 12 
months.  Progression free survival was 6.8 months (95% CI, 5.6-8.1).  
 
Hauschild et al demonstrates an overall survival rate of 57% for Dabrafenib compared to 22% for 
Dacarbazine.  Progression free survival was 5.1 months for Dabrafenib compared to 2.7 months for 
Dacarbazine.    
 
CONCLUSIONS:  All studies reported longer periods of progression free survival and an increase in 
overall response rates.  This suggests that BRAF inhibitors improve survival in patients with V600E 
mutant melanoma. 
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INTRODUCTION 
Melanoma is a form of skin cancer that affects melanocytes.  Melanocytes are found in 
the epidermis and produce melanin, the major pigment responsible for skin color.  Melanoma is 
sometimes described as the “ugly duckling sign”, meaning that it doesn’t look like other nevi.  
Typically nevi suspicious of melanoma are asymmetric, have irregular borders, appear black or 
brown in color, are larger than 6 mm in diameter, and evolve in size, shape, or color (ABCDE 
rule).  Melanoma most commonly occurs on sun exposed areas of the skin but not exclusively.  
In addition, the incidence of melanoma increases with age, however younger patients may also 
be diagnosed with melanoma.1 
Skin cancer is the most commonly diagnosed cancer.  Melanoma accounts for less than 
2% of skin cancer but it is the most deadly.  The American Cancer Society estimates 76,100 new 
cases and 9,710 deaths from melanoma in the United States for 2014.  In addition, the number of 
new cases of melanoma in the US has been increasing for the past 30 years.1  Studies examining 
all stages of disease, indicate the annual cost of treatment ranges from $44.9 million to $932.5 
million.2  It is estimated that there are 17.4 million visits from 1979 to 2010.3 
Risk factors of melanoma include UV light exposure, presence of moles, fair skin, 
freckling, light hair, and positive family history.  However, it is not known how these risk factors 
cause melanoma.  It is known that patients with melanoma are at a higher risk of recurrence.  
However, methods to lower the risk of melanoma progression or recurrence remain unknown.1 
Early stages of melanoma can be treated with surgery alone but more advanced stages 
require additional treatment.  Surgical treatments includes wide excision, lymph node dissection, 
and removal of metastatic disease.  Common immunotherapy includes Ipilimumab, 
Pembrolizumab, Interferon-alpha, Interleukin-2, Bacille Calmette-Guerin (BCG) vaccine, and 
Imiquimod cream.  Targeted therapies include BRAF inhibitors (Vemurafenib and Dabrafenib) 
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and MEK inhibitors (Trametinib).  Typical chemotherapies include Dacarbazine, Temozolomide, 
Nab-paclitaxel, Carmustine, Cisplatin, Carboplatin, and Vinblastine.  Radiation is also a common 
treatment modality.2  Metastatic melanoma has a poor prognosis with an average 8-18 month 
survival rate in patients with stage IV melanoma.  Until 2011, Dacarbazine was the only 
monotherapy approved by the FDA for metastatic melanoma.1,4    
The therapies listed above all play an important role in the treatment of melanoma.  50% 
of melanoma patients have a mutation of the BRAF gene.  BRAF is an oncogene, meaning this 
mutation increases cell proliferation.  Therefore, melanocytes reproduce at an uncontrolled rate, 
resulting in cancer.  BRAF inhibitors are effective in shrinking tumors in half of patients with 
metastatic melanoma with a mutated BRAF gene.1  This paper evaluates two randomized 
controlled trials (RCTs) and one cohort study comparing the efficacy of BRAF inhibitors as a 
therapy for improving survival in patients with BRAF mutant melanoma. 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not “Do BRAF 
inhibitors improve survival in patients with BRAF V600E mutant melanoma?” 
METHODS 
 To examine this question, this paper focuses on patients 18 years or older with stage 
III/IV BRAF V600E mutant melanoma.  Interventions that were considered in literature search 
included BRAF inhibitors, Vemurafenib or Dabrafenib.  Types of studies examined include two 
randomized control trials and one cohort study.  Chapman et al is a phase 3 randomized clinical 
trial comparing Vemurafenib, a BRAF inhibitor, and Dacarbazine, the FDA approved treatment 
for metastatic melanoma at the time of publication.  Overall survival, progression free survival, 
and tumor response were measured.4  Sosman et al is a multicenter phase 2 trial cohort study 
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investigating the efficacy of Vemurafenib with respect to overall response rate, progression free 
survival, and overall survival.5  Hauschild et al is a phase 3 randomized controlled trial that 
compared efficacy of Dabrafenib, a BRAF inhibitor, and Dacarbazine by measuring progression 
free survival and overall survival.6 
 A detailed search was completed using OVID, Medline, and PubMed with the key words 
of “Melanoma”, “BRAF inhibitors”, and “Survival”.  Articles were English language peer 
reviewed publications from 2011 and 2012.  The criteria used for selection was based on 
relevance to the proposed clinical question and patient oriented outcomes (POEMS).  Inclusion 
criteria were at least two randomized control trials.  Exclusion criteria included patients less than 
18 years of age, central nervous system metastasis, and other invasive cancers within five years 
of enrollment.  Statistics that were reported include RBI, ABI, NNT, and 95% Confidence 
interval.  Table 1 provides information regarding inclusion and exclusion criteria and specific 
study interventions. 
 
Table 1: Demographics and Characteristics of Included Studies 
Study Type 
# 
Pts 
Age 
(yr) 
Inclusion Criteria 
Exclusion 
Criteria 
W/
D 
Intervention 
Chapman4 
(2011) 
RCT 675 >18  -previously untreated 
stage IIIC or IV 
melanoma, positive 
for BRAF V600E 
-Life expectancy of 3 
months or longer 
-ECOG performance 
status of 0 (fully 
active) or 1 
(restricted in 
physically strenuous 
activity but 
ambulatory) 
-Adequate 
hematologic, hepatic, 
renal function 
-history of cancer 
within past 5 yrs 
(except basal, 
squamous cell of 
the skin or 
cervical cancer) 
-Metastasis to 
CNS 
3 960 mg of 
Vemurafenib 
PO BID 
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Sosman5 
(2012) 
Cohort 
Study 
132 >18 -Stage IV melanoma 
with BRAF V600 
mutation & 
progressive disease 
after at least one prior 
systemic treatment 
-ECOG performance 
status of 0 (fully 
active) or 1 
(restricted in 
physically strenuous 
activity but 
ambulatory) 
-Brain metastasis 
uncontrolled after 
at least 3 months 
of local therapy 
-Other invasive 
cancers within 5 
yrs from 
enrollment 
-Inadequate 
hematologic, 
hepatic, & renal 
function 
0 960 mg of 
Vemurfenib 
PO BID 
Hauschild
6 (2012) 
RCT 250 21-
93  
-previously untreated 
stage III or IV BRAF 
V600E mutant 
positive melanoma 
-ECOG performance 
status of 0 (fully 
active) or 1 
(restricted in 
physically strenuous 
activity but 
ambulatory) 
-Adequate 
hematologic, hepatic, 
renal, & cardiac 
function 
-surgery, 
radiotherapy, or 
immunotherapy 
within 4 wks 
-History of HIV, 
G6PD, or previous 
cancer in last 5 yrs 
- CNS metastasis 
- Corrected QT 
interval >480ms, 
ACS, stent 
placement, 
arrhythmias, heart 
murmur grade 2 or 
higher 
80 150 mg of 
Dabrafenib 
PO BID 
 
OUTCOMES MEASURED 
 The outcomes measured were overall survival and progression free survival.  Both of 
which are patient oriented evidence that matters (POEMS).  These outcomes were measured 
consistently across the three studies.  Chapman et al measured overall survival, progression free 
survival, and tumor response.  Overall survival is reported as a percent of patients living out of 
the total number of patients that entered a treatment group.  Progression free survival was the 
time from randomization to documented disease progression or death.  Tumor response, a 
decrease in tumor size, was also reported.  Two-sided unstratified log-rank test were used to 
compare survival rates in the two study groups.  Event time distribution was estimated using the 
Kaplan-Meier method.4  In the Sosman et al study, overall response rate was defined as the 
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number of patients with complete or partial response divided by the total number of treated 
patients.  Progression free survival, and overall survival were estimated using the Kaplan-Meier 
method while medians with two-sided 95% confidence intervals were calculated using the 
Brookmeyer and Crowley method.5  Hauschild et al progression free survival and overall 
survival were reported with two-sided 95% confidence intervals.6       
RESULTS 
 At 6 months, Chapman et al reported an overall survival rate of 84% (95% CI, 78-89) for 
Vemurafenib and 64% (95% CI, 56-73) for Dacarbazine.  Progression free survival was 5.3 
months in the Vemurafenib group and 1.6 months in the Dacarbazine group.  65% of patients 
could be evaluated for tumor response.  In the Vemurafenib group, 48% (95% CI, 42-55) of 
patients had a detectable decrease in tumor size (2 patients had a complete response and 104 had 
a partial response) with a median time to response of 1.45 months.  In the Dacarbazine group, 
5% (95% CI, 3-9) of patients experienced a decrease in tumor size (all partial response) with a 
median time to response of 2.7 months.  Tumor response rates between the two groups were 
considered highly significant (P<0.001 with chi-square test).4 
 Sosman et al reported an overall response rate of 53% (95% CI, 44-62) for patients 
receiving Vemurafenib.  6% of patients experienced a complete response while 47% received a 
partial response.  The progression free survival was 6.8 months (95% CI, 5.6-8.1).  The median 
overall survival was 15.9 months (95%, 11.6-18.3).  The overall survival rates at 6, 12, and 18 
months are reported in Table 2.5 
Table 2: Overall Survival Rate of Patients Receiving Vemurafenib 
Time Overall Survival Rate 
6 months 77% (95% CI, 70-85) 
12 months 58% (95% CI, 49-67) 
18 months  43% (95% CI, 33-53) 
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Hauschild et al reported overall survival rate of 57% for patients receiving Dabrafenib 
treatment while overall survival rate for Dacarbazine was 22%.  The median time on study was 
4.9 months.  Progression free survival for the Dabrafenib group was 5.1 months and 2.7 months 
for the Dacarbazine group.  Response rates were reported as 50% (95% CI, 42.4-57.1) for 
Dabrafenib and 6% (95% CI, 1.8-15.5) with a 5.5 month duration of response.6 
Treatment effects of the three studies are displayed in Table 3.  Relative Benefit Increase 
(RBI) represents the increased chance of a positive outcome if treated with a BRAF inhibitor 
compared to the chance of positive outcomes if treated with the control, Dacarbazine.  Absolute 
Benefit Increase (ABI) represents the actual increase in positive outcomes between the treatment 
of BRAF inhibitors and Dacarabazine.  Number Needed to Treat (NNT) was calculated in order 
to describe the number of patients that would need to be treated in order for one patient to 
survive. 
Table 3: Treatment Effects of BRAF Inhibitors in Patients with BRAF V600E Mutant 
Melanoma 
STUDY CER (%) EER (%) RBI (%) ABI (%) NNT (n) 
Chapman et al4 0.64 0.84 0.3125 0.2 5 
Sosman et al5 n/a n/a n/a n/a n/a 
Hauschild et al6 0.22 0.57 1.59 0.35 3 
CER= Control Event Rate; EER= Experimental Event Rate; RBI= Relative Benefit Increase; 
ABI= Absolute Benefit Increase; NNT= Number Needed to Treat 
 
 Most common side effects of Vemurafenib include cutaneous events, arthralgia, fatigue, 
photosensitivity skin reactions.  Cutaneous squamous cell carcinoma, keratoacanthoma, or both 
developed in 18% of patients in the Chapman et al study4 and 26% of patients in the Sosman et 
al study.5  Most common side effects of Dacarbazine include fatigue, nausea, vomiting, and 
neutropenia.4,5,6  Dabrafenib has a similar side effect profile to Vemurafenib.6 
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DISCUSSION 
 Treatment options for metastatic melanoma are limited.  Once the BRAF mutation was 
known to be associated with melanoma, BRAF inhibitors appeared to be a promising target for 
therapy.5  Nearly 50% of patients with melanoma are positive for the BRAF V600 mutation.  
BRAF inhibitors induce a clinical response in more than half of patients that are positive for the 
BRAF V600 mutation.4,5,6  Vemurafenib was approved by the FDA in 2011 for the treatment of 
metastatic melanoma.  Dabrafenib was later approved in 2013.1 
 One of the more common toxic effects related to the use of BRAF inhibitors involved the 
skin.  Cutaneous squamous cell carcinoma and keratoacanthoma were removed with simple 
excision.  Other side effects such as arthralgia, rash, fatigue, and photosensitive reactions were 
primarily managed with dose reduction.4,5,6 
 One important consideration is how BRAF V600 mutant melanomas become resistant to 
BRAF inhibitors.  In all three studies, BRAF inhibitors exhibited progression free survival for at 
least 5 months.  During this time melanomas responded to BRAF inhibitor target therapy.  As 
time progressed, tumors gained resistance and progression occurred.  At this time no mechanism 
of resistance has been identified but is an important consideration for further treatment and 
research.4,5,6 
CONCLUSION 
 Based on the analysis of the three studies, this selective EBM review concludes that 
BRAF inhibitors do indeed improve survival in patients with BRAF V600E mutant melanoma.  
Studies reported improved survival rates of at least 50% and in one study up to 80%.4,5,6  The use 
of BRAF inhibitors for the treatment of BRAF V600E mutant melanoma has shown to decrease 
tumor size, slow the progression of the disease, and ultimately prolong life in patients with 
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metastatic disease.  Future research should be aimed to minimize side effects and also to 
determine the mechanism of resistance in order to prolong tumor response to treatment and 
further improve survival. 
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